IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Beverly L. Davidson et al.

Examiner:

Serial No . 10/522,954

Unknown Group Art Unit: 1635

Filed: January 31, 2005 Docket: 17023.045US2

Title:

ALLELE-SPECIFIC SIRNA-MEDIATED GENE SILENCING

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment Commissioner for Patents P.O. Box 1450

Alexandria, VA 22313-1450

Sir

In compliance with 37 C.F.R. & 1.56, and in accordance with 37 C.F.R. & 1.97 et. sea., the enclosed materials are brought to the attention of the Examiner for consideration in connection with the aboveidentified patent application. Applicants respectfully request that this Information Disclosure Statement be entered and the documents listed on the attached Form 1449 be considered by the Examiner and made of record. Pursuant to MPEP 609, Applicants request that a copy of the Form 1449, initialed as being considered by the Examiner, be returned to the Applicants with the next official communication.

Pursuant to 37 C.F.R. § 1.97, no fee or statement is required with the Information Disclosure Statement. However, the Commissioner is hereby authorized to charge any required fees to Deposit Account No. 503503 in order to have this Information Disclosure Statement considered. The Examiner is invited to contact the Applicants' Representative at the below-listed telephone number if there are any questions regarding this communication.

> Respectfully submitted, Beverly L. Davidson et al. By their Representatives, Viksnins Harris & Padvs PLLP P.O. Box 111098

St. Paul, MN 55111 952 876-4094

Suprinber 08, 200

Reg. No. 44,894

CENTIFICATE: I hereby certify that this correspondence is being transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first, class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents; P.O. Box 1450, Alexandria, V.A 2313-1450, on this Section 15 or 15 or

22313-1450, on this _ day of September, 2006.

Substitute for form 1449A/PTO and/or 1449B/PTO INFORMATION DISCLOSURE	Complete if Known		
STATEMENT BY APPLICANT (Use as many sheets as nacessary)	Application Number	10/522,954	
	Filing Date	January 31, 2005	
	First Named Inventor	Davidson	
	Group Art Unit	1635	
-	Examiner Name	Unknown	
Sheet 1 of 1	Attorney Docket No: 17023,045US2		

US PATENT DOCUMENTS				
Examiner Initials *	US Document Number	Publication Date	Name of Patentee/Applicant of Document	
			·	

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Foreign Document Number (include country code)	Publication Date	Translation (Abstract Only or Full Translation, if applicable)		

	OTHER DOCUMENTS NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Include last name of the first author, "Title of the Article", <u>Title of the Source</u> (book, magazine, journal, serial, symposium, catalog, etc.), <u>Volume-Number</u> , page(s) and (date).	
	Holen et al., "Positional effects of short interfering RNAs targeting the human coagulation trigger Tissue Factor", Nucleic Acids Res., 30(8), 1757-6617 (2002).	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /K.C./

EXAMINER	/Kimberly Chong/	DATE CONSIDERED	03/23/2010